Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMR) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing details share acquisitions by GSK executives on September 9, 2015, executed through the GSK ShareReward Plan. The transaction price was 1317.69 pence per Ordinary Share. No material changes to financial performance or corporate structure are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the acquisition of shares by the following individuals:
- Sir Andrew Witty (20 shares total)
- Mr R G Connor (20 shares total)
- Mr S Dingemans (20 shares total)
- Mr N Hirons (20 shares total)
- Mr D S Redfern (20 shares total)
- Ms C Thomas (20 shares total)
- Mr P C Thomson (18 shares total)
- Dr P J T Vallance (20 shares total)
- Ms E Walmsley (20 shares total)
- Mrs V A Whyte (20 shares total)
Investor Verification Points
- Verify the total number of shares acquired by each PDMR under both the personal contribution and matching elements of the ShareReward Plan.
- Confirm the transaction price of 1317.69 pence per share against market data for September 9, 2015.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly earnings releases for financial metrics.